Ark appoints new CFO and secretary
This article was originally published in Clinica
Ark Therapeutics has promoted David Bowyer to chief financial officer and Edward Bliss to company secretary. Martyn Williams, who recently became CEO of the company, previously held both positions. Mr Bowyer joined Ark (London, UK) in 2004, and was promoted to group financial controller in 2008. Before this, he worked for Deloitte for four years. Dr Bliss, who also holds the position of general counsel, joined Ark in 2005. Previously, he worked for the US law firm Covington & Burling. Ark markets five devices including its Kerraboot dressing and Neuropad diagnostic, and is also developing several pharmaceuticals.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.